Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b
CA 2536256 C · Owner: Philogen S.P.A. · Inventors: Hilger, Christoph-Stephan; Carnemolla, Barbara; Zardi, Luciano
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A specific binding member that binds human ED-B wherein the specific binding , member is labelled with an isotope selected from the group consisting of 76Br 77Br, 123I, 124I, 131I and 211At and comprises an antigen-binding site that comprises an antibody VH domain and an antibody VL domain wherein the , antibody VH domain is selected from the group consisting of the L19 VH domain and a VH domain comprising a VH CDR1, a VH CDR2 and a VH CDR3 wherein the VH , CDR3 is the L19 VH CDR3 of SEQ ID NO. 3 the VH CDR1 is optionally L19 VH CDR1 of SEQ ID NO. 1, and the VH CDR2 is optionally L19 VH CDR2 of SEQ ID NO. 2; and wherein the antibody VL domain is optionally selected from the group …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 1, 2004 and granted February 26, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 1, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 1, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.